Live
FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionFierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery systemPharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streakPromega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent ToolkitBioWorldNME Digest: Q1 2026FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranBioWorldNew York University identifies new analogues of mannose-6-phosphateBioWorldAvelos Therapeutics synthesizes new PARG inhibitorsBioWorldSimcere Zaiming Pharmaceutical discovers new MAPK inhibitorsLabiotechEight oncology deals in 2026 spotlight where industry leaders are betting bigEndpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseases
PharmaVoice 9 déc. 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

Original
Contenu indisponible. Consultez la source originale.